Halloween may be over, but Matthew and Camila McConaughey clearly aren’t ready to let the spooky vibes go just yet. The couple is keeping the party going, Pantalones-style, with a cheeky new photo ...

Denver Fashion Week is happening Nov. 8 to Nov. 16 at The Brighton in Denver, CO. Kansas mayor hit with criminal charges for allegedly voting as noncitizen in several elections Virginia Giuffre's ...

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs like Zepbound and Wegovy in exchange for tariff relief and ...

Two of MomTok's single moms talk to PEOPLE about balancing home life and work life Miranda McWhorter/Instagram The MomTokers are fiercely protective of their children and each other Layla Taylor and ...

Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ...

INDIANAPOLIS — Eli Lilly & Company and Novo Nordisk announced they are cutting prices on their weight loss drugs in a deal cut with the White House. ”It’s truly an honor to be here today for this ...

Every item on this page was chosen by a Town & Country editor. We may earn commission on some of the items you choose to buy. The Lilly Pulitzer x Dee Ocleppo Hilfiger collaboration showcases two ...

Eli Lilly (LLY) is exiting CVS Health’s (CVS) drug benefit plan for its employees after the managed care giant decided to limit access to the company’s popular weight loss drug, Zepbound, in favor of ...

In the closing months of 2025, President Donald Trump’s effort to reshape how Americans pay for prescription drugs has taken clearer form. What started as a campaign threat to slap tariffs on ...

A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history.

Editor's note: This article has been updated to provide clarity on a head-to-head study Eli Lilly conducted on its candidate, orforglipron. A pill version under development of Novo Nordisk's (NVO) GLP ...